Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Mayne Pharma Group ( (AU:MYX) ) just unveiled an update.
Mayne Pharma addresses recent media reports concerning objections to its Scheme transaction with Cosette, particularly regarding the potential closure of its Salisbury manufacturing site. The company clarifies that it has no plans to close the site and highlights its recent financial performance and facility upgrades. Mayne Pharma is seeking further information and considering direct communication with the Foreign Investment Review Board (FIRB) to ensure all necessary information is available for informed decision-making regarding the Scheme.
The most recent analyst rating on (AU:MYX) stock is a Buy with a A$6.10 price target. To see the full list of analyst forecasts on Mayne Pharma Group stock, see the AU:MYX Stock Forecast page.
More about Mayne Pharma Group
Mayne Pharma is an ASX-listed specialty pharmaceutical company that focuses on commercializing novel pharmaceuticals, particularly in dermatology and women’s health in the United States. It also offers contract development and manufacturing services globally and has a 40-year history of innovation in oral drug delivery systems.
YTD Price Performance: 6.24%
Average Trading Volume: 269,767
Technical Sentiment Signal: Buy
Current Market Cap: A$429M
See more insights into MYX stock on TipRanks’ Stock Analysis page.